Background: Nonantibiotic alternatives providing local gut immunity have been rec-
growth-like factor, 2 epidermal growth factor, 3 transforming growth factor-β, 4 and platelet-derived growth factor. 1 Colostral immunoglobulins provide defense in both treatment and prevention of viral and bacterial infections, whereas growth factors promote gut integrity and mucosal recovery in cattle with diarrhea 5 through differentiation of both immature and mature cells in the gastrointestinal tract. [6] [7] [8] Consequently, the benefits of feeding bovine colostrum or colostrum supplements in human patients with diarrhea have been investigated with variable outcomes. Oral supplementation with a bovine colostrum supplement in patients with human immunodeficiency virus (HIV) infection-associated diarrhea results in a dramatic decrease in stool evacuations per day, decrease in self-estimated fatigue, and an increase in body weight. 9 In contrast, supplementation with bovine colostrum in human patients with short bowel syndrome results in an increase in diarrhea with no improvement in intestinal absorption. 10 Diarrhea is the most common disease condition in preweaned dairy calves in the United States, accounting for 56.4% of deaths. 11 In nonsick calves, oral supplementation with immunoglobulin G (IgG) from 2 to 14 days of age reduced frequency of occurrence of diarrhea, and improved daily weight gain. 12 Oral administration of colostrum or immunoglobulin supplements might provide local immunity in the gastrointestinal tract of calves, thereby reducing frequency and/or preventing the occurrence of diarrhea.
Recent legislation, including the Federal Veterinary Feed Directive in 2017 13 and the California Senate Bill-27 in 2018, 14 was enacted into law and recommended judicious use of antibiotics in food producing animals.
Thus, nonantibiotic alternatives for managing diarrhea in calves are an important management strategy in promoting judicious use of antibiotics, thereby minimizing antibiotic resistance. Given the reported benefits of bovine colostrum or immunoglobulin supplements in human and bovine studies and their potential use as nonantibiotic alternatives, investigations on their use for management of calf diarrhea are warranted. We hypothesized that oral supplementation with immunoglobulins in neonatal dairy calves with diarrhea will reduce treatment events, time to resolution of diarrhea, and mortality rates compared with placebo and control calves. The objectives of this study were to determine the effect of oral immunoglobulin supplementation for 14 days on the number of treatment events, time to resolution of diarrhea, and mortality rates in preweaned dairy calves with diarrhea.
| MATERIALS AND METHODS

| Calves and experimental design
A randomized clinical trial was performed on a single 1800-cow milking Jersey dairy farm. The primary outcome of interest was resolution of diarrhea. Sample size was calculated based on a 5% significance level, power of 80%, assumption that control (CONT) group calves (no oral immunoglobulin supplementation) were 2 times or more likely to be treated compared to treatment (TRXT) group calves (oral immunoglobulin supplementation), and a difference of at least 2 treatment days between the CONT (5 days) and TRXT group calves (3 days), an SD of 2 treatment days, and a 20% dropout rate because of loss of follow-up or incomplete records. The total sample size required was 102 calves (34 calves per group).
Adult cows on the farm of study were vaccinated annually with a modified live respiratory disease vaccine containing infectious bovine rhinotracheitis, bovine viral diarrhea, parainfluenza-3, and bovine respiratory syncytial viruses. Additionally, the cows were vaccinated with a multivalent vaccine containing Escherichia coli, rotavirus, and coronavirus during the dry cow period. Newborn calves were separated from the dam within 3 hours after parturition, fed 4 L of pooled pasteurized colostrum (2 feedings of 2 L) within 12 hours, and then housed in individual hutches. Calves were then fed 2 L of pasteurized milk 3 times daily at 6 am, 12 pm, and 8 pm. Calves were fed a commercial calf concentrate recommended for preweaned Jersey calves, containing no antibiotics from 3 days of age to weaning (70 days).
Neonatal heifer calves diagnosed with diarrhea by the authors based on a fecal consistency scoring system 15 and deemed nonseptic based on a septic scoring system 16 were randomly assigned using a random gener- 
| Monitoring of calves, mortality, and serum IgG determination
Fecal consistency of calves was monitored twice daily by the authors based on a fecal scoring system. 15 The volume of milk consumed by 
| Statistical analysis
A commercially available statistical software application was used for all analyses (JMP Pro14, SAS Institute, Cary, North Carolina). Normality of the data was checked using the Shapiro-Wilk test. Mean ± SD
were reported for normally distributed data, whereas median and range were reported for non-normally distributed data. Descriptive statistics for age at enrollment, serum IgG concentrations, and daily milk intake were calculated. Differences in age, serum IgG concentrations, daily milk intake, and fecal scores at enrollment for the 3 groups were compared using a 1-way analysis of variance, Dunnett's, or as a function of group assignment was determined using survival analysis by construction of Kaplan-Meier plots. For the survival analysis, the entry point into the study was at enrollment, and the exit point was at 14 days after enrollment. The specified outcome of interest was resolution of diarrhea based on fecal scoring. At the exit time point, calves that did not have the outcome of interest (resolution of diarrhea) were censored. Differences in time to resolution of diarrhea among the 3 survival plots were compared using the Sidak test. The effect of age at enrollment, serum IgG concentrations, fecal score at enrollment, medical treatments, and daily milk intake as explanatory variables for time to resolution of diarrhea was determined using the Cox proportional hazard model, and subsequent determination of risk ratios. Risk ratios <1 or >1 with a corresponding P < .05 were considered significant. In all analyses P <.05 was significant.
3 | RESULTS
| Age at enrollment, fecal scores, and milk consumption
All data points were non-normally distributed, thus nonparametric tests were used for data analysis. Median (range) age at enrollment for all calves was 9 (1-19) days. Median (range) age at enrollment for the TRXT, PLCB, and CONT group calves were 9 (1-19), 9 (1-19), and 9 (1-17) days, respectively. There were no differences in the calf age at enrollment between TRXT and CONT, PLCB and CONT, or TRXT and PLCB (all P > .99).
T A B L E 1 Nutrient content of the supplements fed to the treatment group (TRXT; N = 34) and placebo group (PLCB; N = Median (range) fecal score at enrolment for all calves was 2 (1-3).
Median (range) fecal score at enrollment for the TRXT, PLCB, and CONT group calves were 2 (1-3), 1 (1-3), and 2 (1-3), respectively.
There was no difference in the median fecal scores at enrollment between TRXT and CONT (P = .72), PLCB and CONT (P = .27), or TRXT and PLCB (P > .99) groups.
Median (range) daily milk consumption for all calves was 3. All calves that were medically treated for diarrhea in each group were administered antibiotics, oral electrolytes, and kaolin pectin. There was no difference (P = .69) in the proportions of calves that were administered antibiotics, oral electrolytes, or kaolin pectin among the groups (TRXT, 79% versus PLCB, 77% versus CONT, 71%). Proportions of calves administered IV fluids in the TRXT, PLCB, and CONT groups were 12% (4/34), 6% (2/34), and 15% (5/34), respectively (P = 0.49). Duration of treatment ranged from 2 to 10 days per calf.
Six calves died during the study period. Of the calves that died, 4 (12%) were from the TRXT, 1 (3%) from the PLCB, and 1 (3%) from the CONT groups (P = .36). The tentative causes of death based on field necropsies in the 6 calves that died were severe dehydration, sepsis, or a combination of dehydration and sepsis.
| Resolution of diarrhea
Median (95% CI) time to resolution of diarrhea for the TRXT, PLCB, and CONT groups were 10.5 (7, 13), 6.5 (3, 9), and 8 (5, 10) days, respectively. Time to resolution of diarrhea was shorter (P = .008) in the PLCB group than in the TRXT group. There was no difference in the time to resolution of diarrhea between the PLCB and CONT (P = .89) or TRXT and CONT groups (P = .08). Kaplan-Meier curves for the 3 groups are depicted in Figure 1 . Age at enrollment (P = .36), serum IgG concentration (P = .49), fecal score at enrollment (P = .11), daily milk consumption (P = .23), and medical treatment (P = .13) were not significant predictors of time to resolution of diarrhea. The risk ratios determined from the Cox proportional hazard model for all covariates are summarized in Table 2 . Several reasons might explain the lack of effect on diarrhea after addition of immunoglobulins in milk in our study. We added 20 g of immunoglobulins per feeding (40 g per day) based on a previous study in calves which reported a reduction in frequency of occurrence of diarrheal disease in nonsick calves when 10 g of IgG was added twice daily to milk replacer. 12 Considering that calves in our study had diarrhea, we estimated that supplementing with twice as much immunoglobulins compared to previous studies 12 would likely produce an effect. The 20 g of immunoglobulins was delivered through 182 g of the powdered supplement, thereby adding solid weight to 2 L of milk.
| DISCUSSION
Any further addition of larger supplement weight to increase the amount of immunoglobulin will likely affect mixing, viscosity, and palatability of the milk leading to decrease in milk and immunoglobulin supplement consumption. Consequently, it is possible that the dose of immunoglobulins in our study was not sufficient to cause an effect when fed to calves with diarrhea. Furthermore, catabolism of immunoglobulins or passage of immunoglobulins through the gastrointestinal tract of calves with diarrhea might be higher than nondiarrheic calves, and thus higher doses of immunoglobulins are required to produce an effect. Effect of supplementation of immunoglobulins might also depend on the identity of the pathogens causing diarrhea. Studies in humans where oral bovine colostrum supplementation resulted in improvement or cessation of diarrhea were associated with management of Cryptosporidium-associated diarrhea in HIV-infected patients. 36 Potentially, response of calves with diarrhea to supplementation with bovine serum-derived immunoglobulin might differ from bovine colostrum-derived immunoglobulin.
The morbidity because of diarrhea in our study was relatively high.
We performed the study during the summer season when ambient temperatures ranged from 32 to 42 C (humidity <60%), and the farm experiences higher incidence of diarrhea during this season. Although all the calves experienced the same weather conditions, higher ambient temperature might affect the combination of viral, bacterial, and protozoal pathogens present in the environment. We performed our study during this season to ensure that our study results and recommendations will be relevant to the period where the farm experiences the highest incidence of diarrhea. Further studies to assess effects of supplementation of immunoglobulins need to determine the effective dose (if any) by feeding calves incremental doses of immunoglobulin supplements. Additionally, it will be desirable for calves to be blocked by failure of immunity status to assess time to resolution of diarrhea, determine the specific pathogens causing the diarrhea, and determine fecal IgG excretion by labeling the oral IgG with markers such as biotin.
| CONCLUSIONS
Results of our study indicate that supplementation of 20 g of immunoglobulins twice daily in milk did not reduce the time to resolution of diarrhea, treatment events, or mortality rate in dairy calves with diarrhea. The hypothesized benefit of conferring local gastrointestinal immunity by addition of immunoglobulins in milk was not evident. We suggest further studies to determine the effective dose of immunoglobulins that might confer local gut immunity in dairy calves with diarrhea.
